Search Results
Feb 05, 2026, 16:30 ET Dauch Corporation Expands Board of Directors
and industrials sector.Both Simon Mackenzie Smith and Fiona MacAulay were former members of the Dowlais Group plc board.Full director bios are available at
More news about: Dauch Corporation
Feb 05, 2026, 14:43 ET ANTIGUA AND BARBUDA CULINARY MONTH RETURNS WITH EXCITING LINEUP OF EVENTS THROUGHOUT MAY 2026
Suzanne Barr, Toronto, Canada and Atlanta, Georgia *Jamaica**Bios and info for each chef can be found
More news about: The Antigua and Barbuda Tourism Authority
Feb 05, 2026, 12:47 ET Lozano Smith Announces Three New Equity Partners
Creek, Fresno, Monterey, Bakersfield, San Luis Obispo, Los Angeles, and San Diego. For more information about Lozano Smith or to see full attorney bios, visit
More news about: Lozano Smith, LLP
Feb 04, 2026, 17:30 ET Research!America to Honor Top Medical and Health Leaders at Advocacy Awards Event
2026 Advocacy Awards webpage for bios of each honoree and details about Research!America's various awards.About Research!America Research!America is a non-profit medical
More news about: Research!America
Feb 04, 2026, 07:00 ET Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
Andreessen Horowitz (a16z) joined Third Arc Bio's existing world-class investor syndicate to further validate the company's approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio's Board of Directors. Proceeds from the financing
More news about: Third Arc Bio
Feb 03, 2026, 08:54 ET Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board
emerging growth companies.In his advisory role, Mr. Brooks will work with Immorta Bio's leadership team as the Company advances its first-in-class, dual-platform approach to addressing aging biology. Immorta Bio's therapeutic platforms include SenoVax™, a senolytic immunotherapy designed to selectively
More news about: Immorta Bio Inc.
Feb 03, 2026, 08:53 ET Ecovia Bio Closes Series B Funding Round Led by Pointe Angels to Expand Manufacturing Capacity
based in the Grosse Pointe communities east of Detroit, Michigan. The funding will support significant expansion of manufacturing capacity at Ecovia Bio's state-of-the-art Livonia facility to meet surging global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid (γ-PGA) and specialty
More news about: Ecovia Bio
Feb 03, 2026, 08:00 ET Dash Bio Expands Operations with 24,000 Square Foot GLP-Compliant Facility in Waltham, MA. February 3, 2026
Dash Bio's new Boston-area facility supports the mission of delivering bioanalysis results in days versus the industry standard of 2-4 months, with expanded capacity for sample storage, additional instrumentation, and next-generation lab automation.WALTHAM, Mass.,
More news about: Dash Bio
Jan 31, 2026, 03:15 ET Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
shares. "This not only ensures survival, but healthy survival."Survival is merely the prerequisite for the future. What truly anchors Sanyou Bio's position is its formidable technological moat.Over ten years, Sanyou Bio has built a 10-trillion–scale Intelligent Super-Trillion Antibody Library,
More news about: Sanyou Bio
Jan 29, 2026, 10:07 ET Avobis Bio Announces Expanded Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial to be Presented at European Crohn's and Colitis Organisation (ECCO) Congress
ClinicalTrials.gov.About Avobis BioAvobis Bio's mission is to transform life for patients with debilitating conditions by harnessing the power of implantable biology to develop curative therapies
More news about: Avobis Bio
Jan 29, 2026, 09:00 ET Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH
Acquisition adds a differentiated, oral, IND-stage asset with multi-indication potential to Formation Bio's rapidly growing portfolio NEW YORK, Jan. 29, 2026 /PRNewswire/ --
More news about: Formation Bio
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
targeting IgG4 applicable to multiple autoimmune conditions. GlycoEra is based in Switzerland and the U.S.Hillstar Bio's $67 million Series A: Co-investing with Droia Ventures, Frazier Life Sciences and Novo Holdings, LifeArc Ventures supported the U.S.-based company's
More news about: LifeArc
Jan 28, 2026, 15:59 ET Pivot Bio Elevates Three Leaders and Announces New Environmental Policy Appointment
officer, with continuing responsibility for leading efforts to expand Pivot Bio's production capabilities and optimizing supply chain performance to meet growing demand. In this role, he is responsible for ensuring Pivot Bio's industry-leading products are produced and delivered to farmers at the right
More news about: Pivot Bio
Jan 28, 2026, 11:00 ET 技嘉深化與 AMD 合作 加速地端 AI 應用落地
功能整合為更清楚且符合工作流程的操作介面，讓使用者減少手動調整，享受強勁且穩定的效能輸出。專為釋放 AMD Ryzen™ 9000 X3D 系列處理器效能而設計的 GIGABYTE X870E X3D 系列主機板，透過獨家 AI 核心技術 X3D Turbo Mode 2.0 調校，可提升遊戲運行的穩定度與反應速度。此技術整合軟硬體，針對 Ryzen X3D 處理器進行最佳化；同時搭配強化的供電設計、BIOS 調校與多項 DIY 友善設計，讓玩家獲得更順暢且穩定的遊戲效能表現。技嘉 OLED 電競螢幕 GIGABYTE MO27Q28GR、MO34WQC36 與 MO32U24 皆通過 AMD FreeSync™ Premium Pro 認證，透過同步螢幕更新率與顯示卡輸出幀率，帶來更平順的 VRR
More news about: GIGABYTE
Jan 28, 2026, 11:00 ET GIGABYTE Deepens Collaboration with AMD to Accelerate On-Device AI for Gaming, Creation, and PC Builds
hardware–software fusion optimized specifically for AMD 3D V-Cache™ Technology behavior, along with a robust power design, refined BIOS, and DIY-friendly features to deliver smooth, consistent gaming performance with less trial-and-error tuning.For
More news about: GIGABYTE
Jan 28, 2026, 06:30 ET Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
molecules, for delivery in a single auto-injector shot for at-home or in-HCP office use. These high concentration formulations are achievable using Surf Bio's proprietary, protective excipient and spray dry approach, enabling accessible and patient-friendly subcutaneous delivery of antibodies and biologics.Table
More news about: Halozyme Therapeutics, Inc.
Jan 27, 2026, 14:07 ET Levine Leichtman Capital Partners Announces Investment Team Promotions
team. We are proud of the depth of talent across the firm, and will continue to build on this momentum to drive long-term growth together."Full bios of the professionals being promoted can be viewed here: llcp.com/team.About Levine Leichtman Capital PartnersLevine Leichtman Capital
More news about: Levine Leichtman Capital Partners, LLC
Jan 26, 2026, 10:00 ET Barnwell Bio Raises $6M to Transform Livestock Health Through Metagenomic Biosurveillance
$14 billion in 2024-2025 alone. Barnwell Bio's platform addresses these challenges by detecting pathogens before clinical symptoms appear, allowing for "gold-standard" biosecurity without sacrificing
More news about: Barnwell Bio
Jan 21, 2026, 10:05 ET ASCAP MUSIC CAFÉ AT THE SUNDANCE FILM FESTIVAL CELEBRATES 28 YEARS IN PARK CITY WITH CREATOR CONVERSATIONS FEATURING KATHLEEN HANNA AND TAMRA DAVIS, AND LIVE PERFORMANCES FROM EMILY BEAR, JOSH KELLEY, FOXY SHAZAM, NATHALIA, RON ARTIS II AND PHOTAY AT THE ACURA HOUSE OF ENERGY ON JANUARY 25 AND 26
intimate performances and conversations from a remarkable lineup of songwriters and composers."See the full schedule and get performer/panelist bios at
More news about: ASCAP - American Society of Composers, Authors and Publishers
Jan 21, 2026, 08:30 ET happyactually Launches Evidence-Based Wellbeing Platform to Transform How People Understand Happiness
Seattle, happyactually aims to set a new standard for clarity, structure, and scientific integrity in the wellbeing technology space.Leadership BiosChief Executive Officer and CPO - Miriam Schwarz: Founder, visionary, and leader of happyactually.Chief Happiness Officer and Scientific
More news about: happyactually LLC
Jan 21, 2026, 08:00 ET Variant Bio Appoints Craig T. Basson, MD, PhD, to Advance Genomics-Driven Clinical Programs
experience translating genetic insights into medicines will be instrumental as we move our programs into the clinic."Dr. Basson added, "Variant Bio's ability to uncover actionable insights from large-scale human genomics represents a powerful opportunity to improve how medicines are discovered and
More news about: Variant Bio
Jan 20, 2026, 10:00 ET Think Bioscience Raises $55M in Oversubscribed Series A
exceedingly difficult. Most proteins in the human proteome are still considered undruggable—that is, they lack an obvious pocket for a drug to bind. Think Bio's synthetic biology platform uses high-throughput functional surveys to find pockets that others miss and uses them to advance small molecules with biochemical
More news about: Think Bioscience
Jan 20, 2026, 09:01 ET ProGro BIO Expands Rhizol Platform with Two New Microbial Products
efficiency makes JumpStart a practical and reliable solution for peanut growers.Phoenix Microbial Soil Recovery Tool Phoenix is ProGro BIO's new microbial soil recovery product designed to help restore soil biological function following harsh agricultural practices. Modern production systems,
More news about: ProGro BIO Inc.
Jan 20, 2026, 09:00 ET MYndspan Shows Impact of Sleep Quality on Brain Function in Real-Time Using MEG Technology
specialist hospitals due to cost and infrastructure requirements. MYndspan is expanding access through partnerships with industry leaders including MEGIN, BIOS Health, and IMEDCO."Neurological conditions are now the leading cause of poor health globally, and a substantial proportion of dementia cases
More news about: MYndspan
Jan 18, 2026, 20:00 ET D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
differentiated KRAS G12D inhibitor targeting both OFF and ON conformations to address one of the most common KRAS mutations. The program aims to broaden D3 Bio's multi‑allele KRAS franchise and deliver new solutions for the heterogeneous and evolving landscape of KRAS‑driven cancers.About D3 BioD3
More news about: D3 Bio